- HER2 negative
- ER positive
- PR positive
- HER2 positive
- ER negative
- PD-L1 positive
- PR negative
- EGFR negative
- ALK negative
- KRAS positive
- Gleason Score 10
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Stage IV
- Stage III
- Stage II
- Stage I
- Adjuvant Therapy (except reconstruction)
- Cancer-Directed Surgery
- Endocrine Therapy (prescription with intent to initiate within 6 weeks after registration)
- Endocrine Therapy (within 6 months prior to registration)
- Endocrine Therapy within 6 months prior to registration
- Neo-Adjuvant Chemotherapy with No Residual Invasive Disease Post-Surgery
- Neo-adjuvant Chemotherapy
- Prescription with intent to initiate Endocrine Therapy within 6 weeks after registration
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
Disease Grade
225 trials
Trials Without a Placebo
Evergreen Park, IL (<50 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication, itepekimab, to see if it is effective in treating COPD in former smokers. The study will also look at the safety and tolerability of the medication.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing injections of a drug called tozorakimab in adults with COPD who have frequent flare-ups. These patients are already on other inhaled treatments but still experience significant symptoms. The drug aims to reduce lung inflammation and prevent these flare-ups.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Waitlist
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests lorundrostat, a drug that lowers blood pressure by blocking a hormone that makes the body hold onto salt and water. It targets patients whose high blood pressure isn't controlled by standard treatments.
Evergreen Park, IL (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing Tozorakimab, a medication that aims to reduce lung inflammation, in adults aged 40 and older with COPD. The goal is to see if it can help them breathe better and have fewer symptoms.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Evergreen Park, IL (<50 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
Evergreen Park, IL (<50 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying avelumab in combination with two other drugs to treat triple negative breast cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Evergreen Park, IL (<50 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a combination of drugs to treat patients with prostate cancer that has spread and is resistant to hormone therapy. The drugs work in different ways to attack the cancer cells.
Efficacy & Safety Awards
No Placebo-Only Group
Evergreen Park, IL (<50 mi)
Waitlist
Phase 1
0 Criteria Met
Eligibility Criteria
Get notified when new Nephrotic Syndrome trials are postedWe'll send you an email whenever new trials are posted
Evergreen Park, IL (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing VX-147, a new drug, in adults and children with a genetic form of kidney disease. The drug aims to reduce the harmful effects of a specific protein in the kidneys.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing vixarelimab, a medication that may help improve lung function, in people with IPF and SSc-ILD. It works by reducing inflammation and scarring in the lungs to help with breathing.
Evergreen Park, IL (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Evergreen Park, IL (<50 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests whether combining apalutamide with another treatment helps men with high-risk prostate cancer undergoing radiation therapy. The treatment aims to block and reduce male hormones that fuel cancer growth, potentially preventing the cancer from spreading. Apalutamide has been developed for treating prostate cancer and has shown effectiveness.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying hormone therapy with or without everolimus to see how well it works in treating patients with breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Evergreen Park, IL (<50 mi)
Waitlist
Unphased1 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test how safe and effective a new Medtronic device is for treating people with overactive bladder or urinary retention.
Efficacy & Safety Awards
No Placebo-Only Group
Oak Lawn, IL (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests BLI5100, an oral medication, in patients with Erosive Esophagitis (EE). It aims to see if BLI5100 can heal the esophagus and maintain its healing.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Oak Lawn, IL (<50 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether adding nivolumab to the usual treatment of encorafenib and cetuximab works better at shrinking tumors in patients with colorectal cancer that has spread or cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Oak Lawn, IL (<50 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether cabozantinib alone or with nivolumab is better than other treatments for patients with a type of lung cancer called non-squamous non-small cell lung cancer. Cabozantinib stops cancer cells from growing, while nivolumab helps the immune system fight the cancer. The goal is to see if these treatments can help patients live longer without their cancer getting worse.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Atrial Fibrillation trials are postedWe'll send you an email whenever new trials are posted
Oak Lawn, IL (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to study the safety and effectiveness of different doses of intravenous magnesium for treating rapid atrial fibrillation."
Efficacy & Safety Awards
Pivotal Trial
Oak Lawn, IL (<50 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injection of a patient's own processed fat tissue to treat knee pain and improve function in people with moderate knee osteoarthritis. The fat tissue is thought to help by cushioning the joint and possibly aiding in healing. This treatment has been studied for its potential to improve pain and function in patients with knee osteoarthritis.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…12